Goldstein D P
Clin Obstet Gynecol. 1975 Dec;18(4):41-60. doi: 10.1097/00003081-197512000-00006.
Gestational chorionic tumors represent a rare biologic system for three reasons: They are a genetic mixture of both male and female; they are unusually responsive to chemotherapy with a high cure rate; and they always secrete hCG, which acts as a reliable cell marker with which to diagnose, to monitor drug therapy, and to follow-up to ensure continued remission. Nongestational chorionic tumors characteristically share only the latter unique attribute. For this reason, endocrine assays, particularly the measurement of hCG, play a vital role in the management of patients with these tumors. However, as the tools with which we work improve, and our understanding increases, it is quite likely that other tumors will be found to make substances that are similarly specific and reliable so as to be utilized in the same way. Already there are tests such as alpha-fetoprotein and carcinoembryonic antigen that are beginning to serve such a role but are not as specific as is hCG. Our experience with chorionic tumors has given us a valuable opportunity to develop techniques to be used for other tumor systems when reliable cell markers become available. When this time comes, we should be able to look forward to improved survival rates, hopefully approaching those obtained with chorionic disease.
妊娠性绒毛膜肿瘤是一种罕见的生物系统，原因有三：它们是男性和女性的基因混合物；它们对化疗异常敏感，治愈率高；它们总是分泌人绒毛膜促性腺激素（hCG），hCG可作为可靠的细胞标志物用于诊断、监测药物治疗以及随访以确保持续缓解。非妊娠性绒毛膜肿瘤仅具有后一种独特特征。因此，内分泌检测，尤其是hCG检测，在这些肿瘤患者的管理中起着至关重要的作用。然而，随着我们使用的工具不断改进，以及我们的认识不断提高，很可能会发现其他肿瘤也会产生同样特异且可靠的物质，从而能以同样的方式加以利用。已经有诸如甲胎蛋白和癌胚抗原等检测开始发挥这样的作用，但不如hCG特异。我们对绒毛膜肿瘤的经验为我们提供了一个宝贵的机会，当可靠的细胞标志物出现时，可开发用于其他肿瘤系统的技术。当这一刻到来时，我们有望提高生存率，有望接近绒毛膜疾病所取得的生存率。
